We report a patient who developed recurrent hepatic artery thrombosis and deep venous thrombosis following orthotopic liver transplantation. Investigations revealed the presence of activated protein C (APC) resistance due to a mutation in the factor V gene in the transplanted liver. The patient’s own peripheral blood cells did not carry the mutation. Although part of factor V is located in the platelets and may be endogenously synthesized by megakaryocytes, this case demonstrates the major clinical importance of hepatic-derived factor V. It may be reasonable to screen liver donors with a history of a thrombotic event for APC, and to consider anticoagulation in the recipients of livers positive for this defect.

Keywords:
Activated protein C resistance, Factor V Leiden, Thrombosis, Liver transplantation
1.
Bertina RM, Koelman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–67.
2.
Tracy PB, Eide LL, Bowie EJW, Mann KG: Radioimmunoassay of factor V in human plasma and platelets. Blood 1982;60:59–63.
3.
Camire RM, Pollak ES, Kaushansky K, Tracy PB: Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998;92:3035–3041.
4.
Gewirtz AM, Shapiro C, Shen YM, Boyd R, Colman RW: Cellular and molecular regulation of factor V expression in human megakaryocytes. J Cell Physiol 1992;153:277–287.
5.
Jorquera JL, Montoro JM, Fernandez MA, Aznar JA, Aznar J: Modified test for activated protein C resistance. Lancet 1994;344:1162–1163.
6.
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–113.
7.
Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, Fait G, Lessing JB: Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9–13.
8.
Velasco F, Villalba R, Fernandez M, de la Mata M, Roman J, Rubio V, Rufian S, Varo E, Pera C, Torres A: Diminished anticoagulant and fibrinolytic activity following liver transplantation. Transplantation 1992;53:1256–1261.
9.
Eid A, Lyass S, Venturero M, Ilan Y, Safadi R, Zamir G, Berlatzky Y, Yurim O: Vascular complications post orthotopic liver transplantation. Transplant Proc 1999;31:1903–1904.
10.
Hirshfield G, Collier JD, Brown K, Taylor C, Frick T, Baglin TP, Alexander GJ: Donor factor V Leiden mutation and vascular thombosis following liver transplantation. Liver Transpl Surg 1998;4:58–61.
11.
Delorme MA, Adams PC, Grant D, Ghent C, Walker IR, Wall WJ: Orthotopic liver transplantation in a patient with combined hemophilia A and B. Am J Hematol 1990;33:136–138.
12.
Clarkson K, Rosenfeld B, Fair J, Klein A, Bell W: Factor XI deficiency acquired by liver transplantation. Ann Intern Med 1992;115:877–879.
13.
Cransac M, Carles J, Bernard PH, Malavialle P, Freyburger G, Winnock S, Saric J: Heterozygous protein C deficiency and dysfibrinogenemia acquired by liver transplantation. Transplant Int 1995;8:307–311.
14.
Blanshard C, Pasi J, Rolles K, Davidson B, Jain S, Burroughs A: Acute Budd-Chiari syndrome treated by liver transplantation in a woman homozygous for factor V Leiden. Eur J Gastroenterol Hepatol 1996;8:925–927.
15.
Foster PA, Varma RR: Phenotypic correction of activated protein C resistance following orthotopic liver transplantation. Blood Coagul Fibrinolysis 1996;7:65–68.
16.
Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, Fowler B, Seligsohn U: Coexistence of hereditary homocystinuria and factor V Leiden – effect on thrombosis. N Engl J Med 1996;334:763–768.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.